Ketoprofen and Ketorolac and Risk of gastrointestinal toxicity
Escitalopram and risk of QT prolongation
Oral Methotrexate – Review on potential fatal overdose due to medication errors
HMG-CoA Reductase Inhibitors and safety the risk of new onset diabetes/impaired glucose metabolism
Rosuvastatin (Crestor) and risk of gynaecomastia
Topiramate – and risk of congenital malformations
Tibolone (Livial) and risk of venous thromboembolism (VTE) and other risks
Effect of Strattera (atomoxetine) on blood pressure and heart rate from review of MAH clinical trial database
Domperidone and risk of QTc prolongation, serious ventricular arrhythmias and sudden cardiac death
Key elements for SmPC and PL regarding Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) for 14 “high risk” substances (for systemic use)
Powder formulations of Plantago ovata seeds and allergic reactions after prolonged occupational exposure
Antipsychotics (conventional and atypical) and use during the third trimester of pregnancy and risk of abnormal muscle movements and/or withdrawal symptoms in newborns
Citalopram and the risk of QT prolongation
Paracetamol use at therapeutic doses in severe hepatic impairment or severe haemolytic anaemia
Hydrochlorothiazide (HCTZ) and use in lactation + consolidated wording for the SmPC and PL of ACE-inhibitors alone or in combination with HCTZ in pregnancy and lactation
Beta-blocking agents for ophthalmic use and systemic adverse drug reactions after ophthalmic administration
Insulin products and risk of cardiac failure with concomitant use of pioglitazone
Fluoroquinolones and risk of QT-interval prolongation
Risk of psychiatric adverse drug reactions to inhaled and intranasal corticosteroids and risk of non-psychiatric systemic adverse drugs reactions to intranasal corticosteroids
Long-Acting Beta Agonists (LABAs) - Increased risk of exacerbation of asthma symptoms
Tamoxifen and the risk of variability in clinical response due to CYP2D6 genetic variants or when given with CYP2D6 inhibitors
Alendronate and the risk of oesophageal cancer
Camphor containing ointments and risk of unintented oral ingestion
Rosuvastatin and higher incidence of diabetes mellitus and gluscose metabolism disorders in healthy individuals without hyperlipidaemia
Isotretinoin and the risk of erythema multiforme
SSRIs and TCAs and the risk of bone fractures
SSRIs, venlafaxine and mirtazapine and the risk of Persistent Pulmonary Hypertension in Neonates (PPHN)
Fluoxetine and the risk of Congenital Malformations
Propylthiouracil and the risk of serious liver injury
Valproic Acid and the risk of interaction with carbapenems
Cyproterone acetate and the risk of meningiomas
Association of HMG-CoA Reductase Inhibitors with safety concerns: sleep disturbances; memory loss; micturition disorders; sexual disturbance; depression; interstitial pneumopathy
Phenytoin-related SJS in association with HLA-B*1502 allele in individuals of Thai or Han Chinese origin
Apomorphine containing products and risk of QT interval prolongation
Short-acting beta agonists and risk of myocardial ischemia
Conventional (Typical) Antipsychotics and increased mortality in elderly people with dementia
Antipsychotics and risk of venous thromboembolism (VTE)
Vigabatrin and MRI abnormalities and movement disorders
Ceftriaxone and the risk of precipitation when given with calcium
Alendronic acid and the risk of stress fractures of the proximal femoral shaft
Additional hypotensive effects following co-administration of non-selective alpha-blockers and phosphodiesterase-5-inhibitors
Hydrochlorothiazide and use during pregnancy
Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin II Receptor Antagonists (AIIRAs): Use during pregnancy & lactation
Bisphosphonates and Atrial fibrillation
Ibuprofen and low dose aspirin interaction
Antiepileptics and suicidal behaviour
Carbamazepine related Stevens Johnson Syndrome and association with HLA-B*1502
Antidepressants and suicidal thoughts and behaviour
